NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or ... in patients with relapsed/refractory high-risk neuroblastoma in the journal Nature Communications. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback